Eiji Suzuki

9.9k citations

183 papers · 6.2k indexed · 2 hit papers · h-index 36

Materials Chemistry top 2%
Renewable Energy, Sustainability and the Environment top 1%
Molecular Biology top 10%
Immunology top 2%
Oncology top 2%

Co-authors: Shogo Mori Steven Μ. Albelda Veena Kapoor Arminder S. Jassar Larry R. Kaiser Kohjiro Hara Masanori Miyashita Nagatoshi Koumura
Topics: Catalytic Processes in Materials Science (33 papers)Catalysis and Oxidation Reactions (20 papers)Breast Cancer Treatment Studies (15 papers)
Cited by: Renewable Energy, Sustainability and the Environment Catalysis Immunology
Journals: Proceedings of the National Academy of Sciences Journal of the American Chemical Society Journal of Clinical Oncology
Partner nations: Japan United States Australia

In The Last Decade

Eiji Suzuki

180 papers receiving 6.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity

2005 848 citations Eiji Suzuki, Steven Μ. Albelda et al. profile →
Alkyl-Functionalized Organic Dyes for Efficient Molecular Photovoltaics

2006 820 citations Eiji Suzuki et al. profile →

Peers

Countries citing papers authored by Eiji Suzuki

Since Specialization

Citations

This map shows the geographic impact of Eiji Suzuki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eiji Suzuki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eiji Suzuki more than expected).

Fields of papers citing papers by Eiji Suzuki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eiji Suzuki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eiji Suzuki. The network helps show where Eiji Suzuki may publish in the future.

Co-authorship network of co-authors of Eiji Suzuki

This figure shows the co-authorship network connecting the top 25 collaborators of Eiji Suzuki. A scholar is included among the top collaborators of Eiji Suzuki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eiji Suzuki. Eiji Suzuki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Acute adverse events of ultra-hypofractionated whole-breast irradiation after breast-conserving surgery for early breast cancer in Japan: an interim analysis of the multi-institutional phase II UPBEAT study 2024 ·Breast Cancer ·(unknown),Takamasa Mitsuyoshi,Yuka Ono,Takahiro Kishi,Yoshiharu Negoro,(unknown),(unknown),Takashi Sakamoto,(unknown),Ryo Ashida,(unknown),(unknown),Hiroaki Tanabe,(unknown),M. Tokiwa,Eiji Suzuki,Chikako Yamauchi,Michio Yoshimura,Takashi Mizowaki,Masaki Kokubo,(unknown)	2
2	Promoters of BRCA testing under insurance coverage for non-metastatic breast cancer patients in Japan: a retrospective cohort study 2022 ·Breast Cancer ·(unknown),(unknown),Yuki Kataoka,(unknown),(unknown),Eiji Suzuki,Hirofumi Suwa	2
3	Kinetic information from dynamic contrast-enhanced MRI enables prediction of residual cancer burden and prognosis in triple-negative breast cancer: a retrospective study 2021 ·Scientific Reports ·(unknown),Maya Honda,Hiroshi Ishiguro,Masako Kataoka,Tatsuki R. Kataoka,Hanako Shimizu,Masae Torii,Yukiko Mori,Nobuko Kawaguchi‐Sakita,Kentaro Ueno,Masahiro Kawashima,Masahiro Takada,Eiji Suzuki,Yuji Nakamoto,Kosuke Kawaguchi,Masakazu Toi	5
4	Usefulness and Prospects of Sentinel Lymph Node Biopsy for Patients With Breast Cancer Using the Medical Imaging Projection System 2021 ·Frontiers in Oncology ·Yuki Nakamura,Masahiro Takada,Michiko Imamura,(unknown),Jiaxi He,(unknown),(unknown),(unknown),Yoshiaki Matsumoto,Kosuke Kawaguchi,Masahiro Kawashima,Eiji Suzuki,Masakazu Toi	8
5	Downregulated ATP6V1B1 expression acidifies the intracellular environment of cancer cells leading to resistance to antibody-dependent cellular cytotoxicity 2020 ·Cancer Immunology Immunotherapy ·(unknown),Eiji Suzuki,Masakazu Hattori,(unknown),Tatsuki R. Kataoka,Masahiro Hirata,(unknown),Takeshi Kotake,(unknown),(unknown),Tomoharu Sugie,Masakazu Toi	16
6	163MO Randomized phase II study of eribulin-based neoadjuvant chemotherapy for triple-negative primary breast cancer patients stratified by homologous recombination deficiency status (JBCRG-22) 2020 ·Annals of Oncology ·Hiroko Bando,Norikazu Masuda,Takashi Yamanaka,Takayuki Kadoya,(unknown),Shigenori E. Nagai,Shoichiro Ohtani,Tomoyuki Aruga,Eiji Suzuki,Yuichiro Kikawa,Hiroyuki Yasojima,Haruo Kasai,Hiroshi Ishiguro,Hidetaka Kawabata,Satoshi Morita,Hironori Haga,Tatsuki R. Kataoka,Ryuji Uozumi,Shinji Ohno,Masakazu Toi	1
7	Gene expression profile of peripheral blood mononuclear cells may contribute to the identification and immunological classification of breast cancer patients 2018 ·Breast Cancer ·Eiji Suzuki,Masahiro Sugimoto,Kosuke Kawaguchi,(unknown),Ryuji Uozumi,(unknown),(unknown),(unknown),Takeshi Kotake,Satoshi Morita,Masakazu Toi	17
8	Neoadjuvant therapy with trastuzumab emtansine and pertuzumab in patients with HER2-positive primary breast cancer (A randomized, phase 2 study; JBCRG-20) 2017 ·Annals of Oncology ·Norikazu Masuda,Shoichiro Ohtani,Toshimi Takano,Kenichi Inoue,Eiji Suzuki,Rikiya Nakamura,Hiroko Bando,(unknown),Kazunari Ishida,Takashi Yamanaka,Katsumasa Kuroi,Hiroyuki Yasojima,Haruo Kasai,(unknown),Takaki Sakurai,Tatsuki R. Kataoka,Satoshi Morita,Shinji Ohno,Masakazu Toi	1
9	Increased expression of endocytosis-Related proteins in rat hippocampus following 10-day electroconvulsive seizure treatment 2016 ·Neuroscience Letters ·(unknown),Kunio Shimizu,Masashi Nibuya,Hiroyuki Toda,Aihide Yoshino,Eiji Suzuki,Takashi Kondo,Hiroshi Fukuda	8
10	Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer 2016 ·Breast Cancer ·Kosuke Kawaguchi,Eiji Suzuki,(unknown),Michio Yamamoto,Satoshi Morita,Masakazu Toi	20
11	Highly selective and precisely controlled aluminum etching by Ar/HBr/CH 2014 ·Japanese Journal of Applied Physics ·Eiji Suzuki,Hiroto Ohtake,(unknown),(unknown),Masaru Sasaki	1
12	The timing of TGF-β inhibition affects the generation of antigen-specific CD8+ T Cells 2013 ·BMC Immunology ·Jon G. Quatromoni,Eiji Suzuki,Olugbenga T. Okusanya,Brendan F. Judy,Pratik Bhojnagarwala,Ollin Venegas,Evgeniy Eruslanov,Jarrod D. Predina,Steven Μ. Albelda,Sunil Singhal	11
13	Effect of Low-Dose Paclitaxel and Docetaxel on Endothelial Progenitor Cells 2009 ·Oncology ·Mariko Muta,(unknown),Yoshimichi Sai,Shigehira Saji,Eiji Suzuki,Tomoyuki Aruga,Katsumasa Kuroi,Gaku Matsumoto,Masakazu Toi,Emi Nakashima	17
14	Early breast cancer 2006 ·International Journal of Clinical Oncology ·(unknown),Masakazu Toi,Shigehira Saji,(unknown),Tomoyuki Aruga,Eiji Suzuki,Shinichiro Horiguchi,Nobuaki Funata,Katsuyuki Karasawa,Noriko Kamata	14
15	Abnormal peripheral circulation in type 2 diabetic patients with normal ankle-brachial index associates with coronary atherosclerosis, large artery stiffness, and peripheral vascular resistance 2005 ·Diabetes Research and Clinical Practice ·(unknown),Eiji Suzuki,Katsuya Egawa,Yoshihiko Nishio,Hiroshi Maegawa,Shigehiro Morikawa,Toshiro Inubushi,Atsunori Kashiwagi	28
16	Optical Magnetic Field Probe with a Loop Antenna Element Doubly Loaded with LiNbO 3 Crystals 2004 ·IEICE Transactions on Electronics ·Eiji Suzuki,(unknown),(unknown),Ken Ichi Arai,Risaburô Sato	6
17	nm23‐H1 reduces in vitro cell migration and the liver metastatic potential of colon cancer cells by regulating myosin light chain phosphorylation 2003 ·International Journal of Cancer ·Eiji Suzuki,(unknown),Kazunori Tsukuda,(unknown),(unknown),Masakazu Murakami,Hiroyoshi Doihara,Nobuyoshi Shimizu	66
18	Hydrogen production from solar light energy by photovoltaic water electrolysis 2001 ·Hemijska industrija ·Takashi Ohmori,(unknown),Yuichi Yamada,Nobuyuki Matsuki,(unknown),Atsuyoshi Nakayama,Hiroaki Mametsuka,Eiji Suzuki	2
19	Establishing apoptosis resistant cell lines for improving protein productivity of cell culture 1997 ·Cytotechnology ·Eiji Suzuki,Satoshi Terada,Hiroshi Ueda,Tetsuo Fujita,(unknown),Shinichi Takayama,John C. Reed	19
20	Characterization and fed-batch culture of hybridoma overexpressing apoptosis suppressing gene bcl-2 1997 ·Cytotechnology ·Satoshi Terada,(unknown),Hiroshi Ueda,Eiji Suzuki	10

About Eiji Suzuki

Eiji Suzuki is a scholar working on Catalysis, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 183 papers that have together received 6.2k indexed citations. Recurring topics across this work include Catalytic Processes in Materials Science (33 papers), Catalysis and Oxidation Reactions (20 papers) and Breast Cancer Treatment Studies (15 papers). The work is most often cited by research in Renewable Energy, Sustainability and the Environment (1.7k citations), Catalysis (450 citations) and Immunology (1.2k citations). Eiji Suzuki has collaborated with scholars based in Japan, United States and Australia. Frequent co-authors include Shogo Mori, Steven Μ. Albelda, Veena Kapoor, Arminder S. Jassar, Larry R. Kaiser, Kohjiro Hara, Masanori Miyashita, Nagatoshi Koumura, Shuiliang Yao and Zhong‐Sheng Wang. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact